Cargando…

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?

Detalles Bibliográficos
Autores principales:	Chehrazi-Raffle, Alexander, Pal, Sumanta Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276505/ https://www.ncbi.nlm.nih.gov/pubmed/32512515 http://dx.doi.org/10.1016/j.ebiom.2020.102812

Ejemplares similares

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma
por: Sheng, Xinan, et al.
Publicado: (2020)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
por: Leonetti, Alessandro, et al.
Publicado: (2017)

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
por: Matsuki, Masahiro, et al.
Publicado: (2017)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
por: Bergerot, Cristiane, et al.
Publicado: (2023)

Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
por: Wang, Ye, et al.
Publicado: (2022)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

The role of everolimus in liver transplantation
por: Ganschow, Rainer, et al.
Publicado: (2014)

Everolimus in Heart Transplantation: An Update
por: Hirt, Stephan W., et al.
Publicado: (2013)

Use of everolimus in liver transplantation
por: Yee, Mei-Ling, et al.
Publicado: (2017)

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent
por: Dalos, Daniel, et al.
Publicado: (2016)

Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2(+/−) Mice Is Superior to Everolimus Alone()
por: Yang, Jian, et al.
Publicado: (2017)

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2020)

The use of everolimus in renal-transplant patients
por: Pascual, Julio
Publicado: (2009)

Everolimus-eluting stents in interventional cardiology
por: Townsend, Jacob C, et al.
Publicado: (2012)

Cellular Effects of Everolimus and Sirolimus on Podocytes
por: Müller-Krebs, Sandra, et al.
Publicado: (2013)

Intermittent everolimus administration for malignant insulinoma
por: Baratelli, Chiara, et al.
Publicado: (2014)

Everolimus in the Treatment of Metastatic Breast Cancer
por: Royce, Melanie E, et al.
Publicado: (2015)

Radiation-Induced Esophagitis Exacerbated by Everolimus
por: Miura, Yuji, et al.
Publicado: (2013)

The Role of Everolimus in Renal Cell Carcinoma
por: Meskawi, Malek, et al.
Publicado: (2015)

Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial
por: Arroyo, Diego A, et al.
Publicado: (2018)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Everolimus – a new approach in the treatment of renal cell carcinoma
por: Anandappa, G, et al.
Publicado: (2010)

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
por: Kmak, Jamie A., et al.
Publicado: (2020)

What Is the Probability of Doing Something New?
por: McDougall, Douglas
Publicado: (2022)

New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus
por: Pasin, Victor Pavan, et al.
Publicado: (2015)

An Update on the Treatment of Papillary Renal Cell Carcinoma
por: Chawla, Neal S., et al.
Publicado: (2023)

The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis
por: Eren, Mehmet Fuat, et al.
Publicado: (2020)

Role of everolimus in the treatment of renal cell carcinoma
por: George, Saby, et al.
Publicado: (2009)

Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses
por: Levitsky, Josh, et al.
Publicado: (2016)

The role of everolimus in treatment of cardiac allograft vasculopathy
por: Watanabe, Tetsu
Publicado: (2013)

Emerging use of everolimus in the treatment of neuroendocrine tumors
por: Gajate, Pablo, et al.
Publicado: (2017)

Everolimus Implicated in Case of Severe Gastrointestinal Hemorrhage
por: Gonzales, Paul, et al.
Publicado: (2017)

Everolimus in Invasive Malignant Renal Epithelioid Angiomyolipoma
por: Guo, Gang, et al.
Publicado: (2021)

SAT623 Everolimus For Treatment-refractory Prolactinomas
por: Lin, Andrew L, et al.
Publicado: (2023)

Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma
por: Tremblay, Gabriel, et al.
Publicado: (2019)

Antimycobacterial Effects of Everolimus in a Human Granuloma Model
por: Ashley, David, et al.
Publicado: (2020)

Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors
por: Oberstein, Paul E., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7j7pvqdqj91kj82e3j346fpq90